Literature DB >> 18945786

The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection.

Nadia R Roan1, Jan Münch, Nathalie Arhel, Walther Mothes, Jason Neidleman, Akiko Kobayashi, Karen Smith-McCune, Frank Kirchhoff, Warner C Greene.   

Abstract

Human semen contains peptides capable of forming amyloid fibrils termed semen-derived enhancer of viral infection (SEVI) that can greatly increase human immunodeficiency virus (HIV) infection. While SEVI appears to enhance virion attachment to target cells, its underlying mechanism of action is unknown. We now demonstrate that the intrinsic positive charges of SEVI (pI = 10.21) facilitate virion attachment to and fusion with target cells. A mutant form of SEVI in which lysines and arginines are replaced with alanines retains the ability to form amyloid fibrils but is defective in binding virions and enhancing infection. In addition, the interaction of wild-type SEVI with virions and the ability of these fibrils to increase infection are abrogated in the presence of various polyanionic compounds. These anionic polymers also decrease the enhancement of HIV infection mediated by semen. These findings suggest that SEVI enhances viral infection by serving as a polycationic bridge that neutralizes the negative charge repulsion that exists between HIV virions and target cells. Combinations of agents that neutrale SEVI action and produce HIV virucidal effects are an attractive future direction for microbicide development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945786      PMCID: PMC2612336          DOI: 10.1128/JVI.01366-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

Review 1.  RANTES: a versatile and controversial chemokine.

Authors:  V Appay; S L Rowland-Jones
Journal:  Trends Immunol       Date:  2001-02       Impact factor: 16.687

2.  Vaginal pH neutralization by semen as a cofactor of HIV transmission.

Authors:  Jean-Pierre Bouvet; Gérard Grésenguet; Laurent Bélec
Journal:  Clin Microbiol Infect       Date:  1997-02       Impact factor: 8.067

Review 3.  Vaginal microbicides: moving ahead after an unexpected setback.

Authors:  Janneke Hhm van de Wijgert; Robin J Shattock
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

Review 4.  Exploiting common targets in human fertilization and HIV infection: development of novel contraceptive microbicides.

Authors:  Gustavo F Doncel
Journal:  Hum Reprod Update       Date:  2005-09-19       Impact factor: 15.610

5.  The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity.

Authors:  A Trkola; C Gordon; J Matthews; E Maxwell; T Ketas; L Czaplewski; A E Proudfoot; J P Moore
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 6.  Sulfated polysaccharides extracted from sea algae as potential antiviral drugs.

Authors:  M Witvrouw; E De Clercq
Journal:  Gen Pharmacol       Date:  1997-10

7.  Unilamellar liposomes made with the French pressure cell: a simple preparative and semiquantitative technique.

Authors:  R L Hamilton; J Goerke; L S Guo; M C Williams; R J Havel
Journal:  J Lipid Res       Date:  1980-11       Impact factor: 5.922

8.  Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation.

Authors:  Howard E Davis; Matthew Rosinski; Jeffrey R Morgan; Martin L Yarmush
Journal:  Biophys J       Date:  2004-02       Impact factor: 4.033

9.  Semen-derived amyloid fibrils drastically enhance HIV infection.

Authors:  Jan Münch; Elke Rücker; Ludger Ständker; Knut Adermann; Christine Goffinet; Michael Schindler; Steffen Wildum; Raghavan Chinnadurai; Devi Rajan; Anke Specht; Guillermo Giménez-Gallego; Pedro Cuevas Sánchez; Douglas M Fowler; Atanas Koulov; Jeffery W Kelly; Walther Mothes; Jean-Charles Grivel; Leonid Margolis; Oliver T Keppler; Wolf-Georg Forssmann; Frank Kirchhoff
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

Review 10.  How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?

Authors:  Kalpana Gupta; Per Johan Klasse
Journal:  PLoS Med       Date:  2006-02-28       Impact factor: 11.069

View more
  98 in total

1.  Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection.

Authors:  Franziska Arnold; Jacqueline Schnell; Onofrio Zirafi; Christina Stürzel; Christoph Meier; Tanja Weil; Ludger Ständker; Wolf-Georg Forssmann; Nadia R Roan; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

2.  Seminal plasma and semen amyloids enhance cytomegalovirus infection in cell culture.

Authors:  Qiyi Tang; Nadia R Roan; Yasuhiro Yamamura
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation.

Authors:  Stuart A Sievers; John Karanicolas; Howard W Chang; Anni Zhao; Lin Jiang; Onofrio Zirafi; Jason T Stevens; Jan Münch; David Baker; David Eisenberg
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

4.  The amyloidogenic SEVI precursor, PAP248-286, is highly unfolded in solution despite an underlying helical tendency.

Authors:  Jeffrey R Brender; Ravi Prakash Reddy Nanga; Nataliya Popovych; Ronald Soong; Peter M Macdonald; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2011-01-22

5.  Helical conformation of the SEVI precursor peptide PAP248-286, a dramatic enhancer of HIV infectivity, promotes lipid aggregation and fusion.

Authors:  Jeffrey R Brender; Kevin Hartman; Lindsey M Gottler; Marchello E Cavitt; Daniel W Youngstrom; Ayyalusamy Ramamoorthy
Journal:  Biophys J       Date:  2009-11-04       Impact factor: 4.033

6.  Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper.

Authors:  Sarah R Sheftic; Jessica M Snell; Suman Jha; Andrei T Alexandrescu
Journal:  Eur Biophys J       Date:  2012-08-21       Impact factor: 1.733

7.  Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy.

Authors:  Cecilia T Costiniuk; Colin Kovacs; Jean-Pierre Routy; Joel Singer; Sanjay Gurunathan; Rafick-Pierre Sekaly; Jonathan B Angel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-25       Impact factor: 2.205

8.  A molecular tweezer antagonizes seminal amyloids and HIV infection.

Authors:  Edina Lump; Laura M Castellano; Christoph Meier; Janine Seeliger; Nelli Erwin; Benjamin Sperlich; Christina M Stürzel; Shariq Usmani; Rebecca M Hammond; Jens von Einem; Gisa Gerold; Florian Kreppel; Kenny Bravo-Rodriguez; Thomas Pietschmann; Veronica M Holmes; David Palesch; Onofrio Zirafi; Drew Weissman; Andrea Sowislok; Burkhard Wettig; Christian Heid; Frank Kirchhoff; Tanja Weil; Frank-Gerrit Klärner; Thomas Schrader; Gal Bitan; Elsa Sanchez-Garcia; Roland Winter; James Shorter; Jan Münch
Journal:  Elife       Date:  2015-08-18       Impact factor: 8.140

Review 9.  Innate immunity against HIV: a priority target for HIV prevention research.

Authors:  Persephone Borrow; Robin J Shattock; Annapurna Vyakarnam
Journal:  Retrovirology       Date:  2010-10-11       Impact factor: 4.602

Review 10.  When is it time for reverse transcription to start and go?

Authors:  Marylène Mougel; Laurent Houzet; Jean-Luc Darlix
Journal:  Retrovirology       Date:  2009-03-04       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.